Abstract
There is increasing evidence that acute bacterial and viral infection represent trigger factors that temporarily elevate the risk of ischemic stroke. During and after influenza epidemics vascular death rates and hospitalizations for stroke are increased. Influenza vaccination is an effective measure to reduce hospitalization and mortality in the elderly and work incapacity in adults of working age. Results of several observational studies support the hypothesis that influenza vaccination is associated with reduced odds of stroke. As randomized studies are lacking, a causal role of influenza vaccination in stroke prevention is not proven, however. According to current guidelines in many countries, that recommend the vaccination in all patients with chronic vascular disease, all patients with a history of stroke or TIA should receive an influenza vaccination annually. Furthermore, patients with diabetes mellitus or with a combination of risk factors that increase stroke risk should obtain the vaccination. In addition, there is evidence from observational data that the neuraminidase inhibitor oseltamivir reduces the risk of stroke within 6 months after influenza infection.
Keywords: Acute infections, influenza, stroke, risk factor, cerebral ischemia, vascular disease, vaccination, antivirals
Infectious Disorders - Drug Targets
Title: Influenza and Stroke Risk: A Key Target Not to be Missed?
Volume: 10 Issue: 2
Author(s): Christian Urbanek, Frederick Palm and Armin J. Grau
Affiliation:
Keywords: Acute infections, influenza, stroke, risk factor, cerebral ischemia, vascular disease, vaccination, antivirals
Abstract: There is increasing evidence that acute bacterial and viral infection represent trigger factors that temporarily elevate the risk of ischemic stroke. During and after influenza epidemics vascular death rates and hospitalizations for stroke are increased. Influenza vaccination is an effective measure to reduce hospitalization and mortality in the elderly and work incapacity in adults of working age. Results of several observational studies support the hypothesis that influenza vaccination is associated with reduced odds of stroke. As randomized studies are lacking, a causal role of influenza vaccination in stroke prevention is not proven, however. According to current guidelines in many countries, that recommend the vaccination in all patients with chronic vascular disease, all patients with a history of stroke or TIA should receive an influenza vaccination annually. Furthermore, patients with diabetes mellitus or with a combination of risk factors that increase stroke risk should obtain the vaccination. In addition, there is evidence from observational data that the neuraminidase inhibitor oseltamivir reduces the risk of stroke within 6 months after influenza infection.
Export Options
About this article
Cite this article as:
Urbanek Christian, Palm Frederick and Grau J. Armin, Influenza and Stroke Risk: A Key Target Not to be Missed?, Infectious Disorders - Drug Targets 2010; 10 (2) . https://dx.doi.org/10.2174/187152610790963474
DOI https://dx.doi.org/10.2174/187152610790963474 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Phytocompounds as Potential Agents to Treat Obesity-Cardiovascular Ailments
Cardiovascular & Hematological Agents in Medicinal Chemistry Diabetic Retinopathy and Atherosclerosis: is there a Link?
Current Diabetes Reviews Parathyroid Hypertension: A Rare, but Curable form of Secondary Hypertension
Current Hypertension Reviews Parkinsons Disease: Genetics and Beyond
Current Neuropharmacology Over-nutrition, Obesity and Insulin Resistance in the Development of β-Cell Dysfunction
Current Diabetes Reviews Actions of Relaxin on Non-Reproductive Tissues
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Cancer “Stemness”- Regulating MicroRNAs: Role, Mechanisms and Therapeutic Potential
Current Drug Targets Acute Myocardial Infarction: High Risk Ventricular Tachyarrhythmias and Admission Glucose Level in Patients with and without Diabetes Mellitus
Current Diabetes Reviews Resistance to Aspirin and Thienopyridines in Diabetes Mellitus and Metabolic Syndrome
Current Vascular Pharmacology Aldose Reductase Enzyme and its Implication to Major Health Problems of the 21st Century
Current Medicinal Chemistry Folic Acid Can Contribute to Memory Deficit and Na+, K+- ATPase Failure in the Hippocampus of Adolescent Rats Submitted to Hypoxia- Ischemia
CNS & Neurological Disorders - Drug Targets Endothelial Dysfunction: Methods of Assessment and Application to Hypertension
Current Pharmaceutical Design Editorial: Modifying Cardiovascular Risk Factors: Acquired Topics and Emerging Concepts
Current Pharmaceutical Design Genetic Variations of the Hemostatic System as Risk Factors for Venous and Arterial Thrombotic Disease
Current Genomics The Unaddressed Issue of Optimal Antithrombotic Treatment after Coronary Artery Stenting in Patients with an Indication for Anticoagulation: Current Evidence and Suggested Practice
Vascular Disease Prevention (Discontinued) New therapeutic effects of cilostazol in patients with ischemic disorders
Current Vascular Pharmacology L-Type Calcium Channels
Current Pharmaceutical Design Nucleic Acid-Based Aptamers: Applications, Development and Clinical Trials
Current Medicinal Chemistry Melatonin Prevents Hyperhomocysteinemia and Neural Lipid Peroxidation Induced by Methionine Intake
Current Neurovascular Research Can Host Cell Proteins Like ACE2, ADAM17, TMPRSS2, Androgen Receptor be the Efficient Targets in SARS-CoV-2 Infection?
Current Drug Targets